ReportGem ReportGem

U.S. COMPANY FILING

NORTHROP GRUMMAN CORP /DE/ — Form 10-Q filed 2026-04-21

Filed: 2026-04-21Company: NORTHROP GRUMMAN CORP /DE/Ticker: NOCExchange: NYSEForm: 10-QReport period: 2026-03-31SEC accession: 0001133421-26-000016Event: earningsMateriality: 85

Filing text preview

Northrop Grumman reported Q1 2026 sales of $9.881 billion, up 4.4% YoY, and net earnings of $875 million, up 82% YoY, with diluted EPS of $6.14 vs $3.32. The B-21 program loss provision decreased, and Aeronautics Systems swung to profit. The company repurchased shares and announced a B-21 production rate increase agreement with the U.S. Air Force.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-04-21Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-20Nocera Files 8-K Disclosing Material Agreement and Management Changes2026-08-20Sinocell: SCTB10 injection obtains clinical trial approval2026-08-19Sinocell: Subsidiary SCTA02A Injection Gets Clinical Trial Approval2026-08-19Sinocell: Subsidiary SCTB10 Gets Clinical Trial Approval for Hemophilia A2026-08-1910-Q2026-07-21 · 10-Q